Clinical trials: Chronic Heart Failure (CHF)
Chronic Heart Failure
Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
- Trial name
- NCT01541202
- Testing
- rhNRG-1
- Where
- 46 sites in China
- Volunteers
- 679 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Ischemic Heart Failure, Chronic Heart Failure
Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure
This study is designed to evaluate the safety and efficacy of allogeneic induced pluripotent cell derived cardiomyocytes (iPSC-CMs) in treating patients with worsening ischemic heart failure undergoing coronary artery bypass…
- Trial name
- NCT05566600
- Testing
- Human (allogeneic) iPS-cell-derived cardiomyocyte
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Chronic Heart Failure
Heart Failure (HF) Interatrial Shunt Study 1
The objective of this study, is to assess the safety and performance of an interatrial shunt when implanted in patients with severe chronic heart failure.
- Trial name
- NCT02511912
- Testing
- V-Wave
- Where
- Israel
- Sponsor
- V-Wave Ltd
Heart Failure, Renal Insufficiency
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate renal impairment will be randomized (1:1) to…
- Trial name
- NCT02603614
- Testing
- Cenderitide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Capricor Inc.
Chronic Heart Failure
A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions
This is an observational study in which data from Japanese people with chronic heart failure who will be receiving vericiguat is studied.
- Trial name
- NCT05666518
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of care
- Where
- Japan
- Volunteers
- 1,400 people
- Sponsor
- Bayer
Congestive Heart Failure
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function
This is a randomized, double-blind, placebo-controlled, multi-center, sequential cohort study in subjects with congestive heart failure (CHF) and impaired renal function who are on stable furosemide treatment (³ 40 mg daily).
- Trial name
- NCT00568009
- Testing
- SLV320
- Where
- 72 sites in United States, Argentina and 8 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Hypervolemic Hyponatremia
International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia
To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.
- Trial name
- NCT00876876
- Testing
- Lixivaptan
- Volunteers
- 300 people
- Sponsor
- CardioKine Inc.
Heart Failure
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in…
- Trial name
- GALACTIC-HF (NCT02929329)
- Testing
- Omecamtiv Mecarbil, Standard of Care
- Where
- 1,033 sites in United States, Argentina and 34 more
- Volunteers
- 8,256 people
- Sponsor
- Cytokinetics
Acute Heart Failure
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 1 (NCT01065077)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 59 sites in United States, Austria and 15 more
- Volunteers
- 12 people
- Sponsor
- Bayer
Hyperkalemia
An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart Failure
This prospective observational research will be conducted to assess the burden of hyperkalemia including treatment and disease burden of patients in a long-term continuous care from various aspects including adherence to the…
- Trial name
- HK registry (NCT05297409)
- Where
- 32 sites in Japan
- Volunteers
- 352 people
- Sponsor
- AstraZeneca
Chronic Heart Failure, Iron Deficiencies
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
The goal of this clinical trial is to learn if the IV Iron treatment ferric derisomaltose helps in the treatment of chronic heart failure in people with iron deficiency.
- Trial name
- ICONIC-HF (NCT06929806)
- Testing
- Ferric Derisomaltose
- Where
- United States
- Volunteers
- 1,900 people
- Sponsor
- Pharmacosmos A/S
Heart Failure
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.
- Trial name
- NCT01598740
- Testing
- CLP, Spironolactone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sorbent Therapeutics
Heart Failure
Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients
The CardioKinetix Ventricular Partitioning Device (VPD) is intended to isolate the malfunctioning portion of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease.
- Trial name
- PARACHUTE (NCT00573560)
- Testing
- VPD Implant System
- Where
- 7 sites in United States, Serbia
- Volunteers
- 20 people
- Sponsor
- CardioKinetix, Inc
Congestive Heart Failure, Chronic Kidney Diseases
Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects
The study will evaluate the within-subject variability of 20mg ER torsemide as compared to 20mg IR torsemide (Demadex) in fully replicate double-crossover trial in healthy volunteers, who are consuming a high-salt diet (300…
- Trial name
- NCT03214874
- Testing
- Demadex 20mg Tablet, ER Torsemide 20mg Tablet
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of…
- Trial name
- ASTRAAS-HF (NCT04836182)
- Testing
- IONIS-AGT-LRx
- Where
- 19 sites in United States, Hungary and 1 more
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Heart Failure
V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure
The purpose of the trial is to evaluate the safety, usability and performance of the V-LAP™ System in adult subjects with New York Heart Association (NYHA) Class III Heart Failure.
- Trial name
- VECTOR-HF (NCT03775161)
- Testing
- V-LAP™ System
- Where
- 2 sites in Germany, Italy
- Volunteers
- 45 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Pediatric Chronic Heart Failure
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
This is multicenter, single-arm, non-interventional, centrally enrolled specified drug-use survey to investigate the safety of Entresto Tablets or Entresto Granules for Pediatric in pediatric patients with chronic heart failure…
- Trial name
- NCT06659393
- Where
- 28 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Systolic Heart Failure
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of IvabRadine hemisulfate Sustained-release…
- Trial name
- FIRST (NCT02188082)
- Testing
- IvabRadine hemisulfate Sustained-release Tablets
- Where
- 12 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Heart Failure
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium.
- Trial name
- NCT01130597
- Testing
- patiromer, spironolactone
- Where
- 13 sites in Georgia, Slovenia
- Volunteers
- 63 people
- Sponsor
- Relypsa, Inc.